Recent News

ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug June 14, 2017ACEA Biosciences today announced the completion of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor, which is in development for the treatment of B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy subjects participated in the double-blind, placebo-controlled trial, which served to evaluate AC0058’s safety, tolerability, pharmacokinetics, pharmacodynamics, ... Read More
ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy June 5, 2017MSK and ACEA will evaluate whether patient-specific ex-vivo cancer immunotherapy assays are predictive of in vivo efficacy. ACEA Biosciences and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaboration to evaluate a personalized ex vivo potency assay using cancer patients’ malignant pleural effusions and ACEA’s xCELLigence Real-Time Cell Analysis (RTCA) instrument to monitor destruction of the cancer cells ... Read More
Bacterial Biofilm Infections: Personalizing Patient Treatment May 23, 2017Research scientists and physicians aim to use real-time cell analysis instruments to quickly characterize, ex vivo, the antibiotic susceptibility of bacterial biofilm infections prior to treating patients Bacterial biofilms, surface adherent communities of bacteria that are encased in a secreted extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum disease and ... Read More
ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer May 3, 2017ACEA Biosciences continues to innovate and improve its already flexible and easy to use NovoCyte Flow Cytometry system by developing new capabilities to expand users’ breadth of options. The NovoCyte system with its updated software and firmware provides broader versatility and flexibility with its multi-option optical configuration capabilities. This update also brings the release of the new ACEA NovoCyte 3005 ... Read More
Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World April 7, 2017Researchers from academia, industry, and federal agencies convened in Washington, D.C. this week to discuss recent progress in diverse areas of basic and applied cancer research. As a forum to promote scientific exchange and collaboration among scientists working at the forefront of cancer related disciplines, ACEA Biosciences hosted its annual Cancer and Immunotherapy symposium March 31-April 1 at the Renaissance ... Read More
View all News

  Upcoming Events

SPS | September 24-27, 2017 | BerlinAfter our Cardio Symposium, join ACEA Biosciences at the Safety Pharmacology Society’s (SPS) annual meeting and visit us at booth #312.  More details coming soon.Read More
EuroBiofilm | September 19-22 | AmsterdamJoin us at EuroBiofilms and visit us at booth #708 to see scientists to present their most recent data and exchange novel information on clinical, environmental and basic aspects of microbial biofilms.   More details coming soon.Read More
Imm-Oncology | August 28 – September 1 | Boston, MAJoin ACEA Biosciences at Immuno-Oncology Summit in Boston, August 28 – September 1. Stop by our booth #21! The Immuno-Oncology Summit will return to with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers. This year’s ... Read More
View all Events

  ACEA Newsletter

Sign up for the ACEA Newsletter.

View ACEA Newsletters